{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-106631","form_type":"8-K","ticker":"TECH","cik":"0000842023","company_name":"BIO-TECHNE Corp","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.339323+00:00","generated_at":"2026-05-17T00:28:57.541372+00:00","sec_items":["2.02","5.07","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Bio-Techne Q1 FY2026 revenue down 1% to $286.6M; adjusted EPS flat $0.42; declares $0.08 dividend","bullets":["Revenue $286.6M (-1% YoY); GAAP EPS $0.24 (up from $0.21); adjusted EPS $0.42 (flat).","Protein Sciences segment rev $202.2M (-1% YoY); op margin 38.4% vs 39.4%.","Diagnostics & Spatial Biology rev $79.5M (-4%), organic +3%; op margin 11.2% vs 5.1% (benefited from Exosome divestiture).","Completed Exosome Diagnostics divestiture; CEO notes biotech funding headwinds but stability in US academic.","Declares quarterly dividend $0.08/share, payable Nov 28 to holders of record Nov 17."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-106631","json":"https://secwatch.observer/filing/0001104659-25-106631.json","markdown":"https://secwatch.observer/filing/0001104659-25-106631.md","text":"https://secwatch.observer/filing/0001104659-25-106631.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/842023/000110465925106631/0001104659-25-106631-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/842023/000110465925106631/tech-20251030x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:28:57.541372+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}